Leptin and ghrelin concentrations and weight loss in Parkinson’s disease

Fiszer, Urszula; Michałowska, Małgorzata; Baranowska, B; Woliñska-Witort, Ewa; Jeske, W; Jethon, Marta; Piaścik-Gromada, Marta; Marcinowska-Suchowierska, Ewa

doi:10.1111/j.1600-0404.2009.01185.x

Cited by 76 publications

(69 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[150][151][152][153][154][155] Successful DBS treatment is associated with weight gain. 156,157 Loss of smell is frequent in PD, as in other neurodegenerative disorders (e.g.…”

Section: Othersmentioning

confidence: 99%

Non-motor Symptoms in Parkinson’s Disease

Uç¹,

Tippin²,

Chou³

et al. 2011

US Neurology

View full text Add to dashboard Cite

In addition to typical motor dysfunction (parkinsonism), diverse non-motor symptoms (NMS) are frequently observed in patients with Parkinsons disease (PD). Some NMS may antedate the diagnosis of PD. Examples of NMS include cognitive impairment, autonomic dysfunction, visual dysfunction, sleep abnormalities, and psychiatric disorders. NMS are associated with wide-ranging abnormalities in extranigral dopaminergic systems and non-dopaminergic (e.g. cholinergic, noradrenergic, serotoninergic) systems. The type and severity of NMS vary based on age, disease severity, and predominant motor symptoms. NMS can be disabling and reduce quality of life. Treatment of NMS can be challenging. Some NMS are helped by dopaminergic treatment, whereas others can be induced or exacerbated by treatments that help the motor dysfunction. Physicians should probe their PD patients about their NMS and address them for better care. Clinical trials should incorporate NMS as outcomes for more meaningful conclusions on the effect of treatments under investigation.

show abstract

“…[150][151][152][153][154][155] Successful DBS treatment is associated with weight gain. 156,157 Loss of smell is frequent in PD, as in other neurodegenerative disorders (e.g.…”

Section: Othersmentioning

confidence: 99%

Non-motor Symptoms in Parkinson’s Disease

Uç¹,

Tippin²,

Chou³

et al. 2011

US Neurology

View full text Add to dashboard Cite

show abstract

“…A recent study has also shown that renin-angiotensin system blockers might play a beneficial role in AD subjects by modulating the serum leptin level and slowing down cognitive decline [92]. Isolated studies have shown lower serum leptin levels in PD patients [93,94]. Fiszer et al in their study involving 11 PD patients with unintentional weight loss, 16 patients with no weight loss, and 12 control subjects have shown that the mean leptin concentration in plasma is lower in PD patients with weight loss as well as in all PD patients than in control subjects [93].…”

Section: Clinical Studies: Leptin Cognition and Memorymentioning

confidence: 99%

“…Isolated studies have shown lower serum leptin levels in PD patients [93,94]. Fiszer et al in their study involving 11 PD patients with unintentional weight loss, 16 patients with no weight loss, and 12 control subjects have shown that the mean leptin concentration in plasma is lower in PD patients with weight loss as well as in all PD patients than in control subjects [93]. Likewise, another study has reported a lower, but statistically nonsignificant, serum leptin level in weightlosing PD subjects than their weight-stable counterparts [95].…”

Section: Clinical Studies: Leptin Cognition and Memorymentioning

confidence: 99%

Clinicotherapeutic Potential of Leptin in Alzheimer’s Disease and Parkinson’s Disease

Munshi

Khemka

Banerjee

et al. 2014

Asian Journal of Neuroscience

View full text Add to dashboard Cite

Chronic neurodegenerative diseases are a group of devastating neurological disorders that result in significant morbidity and mortality in the elderly population worldwide. Recent researches have shown some interesting associations of the classical antiobesity hormone leptin with two most important neurodegenerative diseases-Alzheimer's disease (AD) and Parkinson's disease (PD). Although several clinical studies have found the procognitive and memory-enhancing role of this peptide hormone in leptin-deficient patients, surprisingly it has not been used in any clinical trials involving patients with developing or fullblown neurodegenerative conditions. This review article is an attempt to bring together the existing information about the clinical associations of leptin with AD and PD. It starts with the basic understanding of leptin action in the brain and its derangements in these diseases and eventually discusses the potential of this hormone as a neuroprotective agent in clinical scenario.

show abstract

“…The findings in this interesting study, in which plasma leptin levels were reduced and IGF-1 levels were elevated, confirm that altered plasma leptin concentrations are common in PD patients. Altered plasma concentrations of orexigenic and anorexigenic peptides (ghrelin and leptin, respectively) lead to alterations in the hypothalamic-pituitary axis 8 . However, PD patients who undergo neurosurgery for a deep brain stimulation (DBS) implant in the subthalamic nucleus can exhibit significant weight gain, underscoring the complex interaction between the hypothalamic-pituitary axis and the basal ganglia 3,5,7,9 .…”

mentioning

confidence: 99%

“…This pooled data from seven studies and demonstrated that PD patients had a significantly lower BMI than controls, and that patients at Hoehn-Yahr stage 3 had lower BMI in comparison to patients at stage 2 7 . Fiszer et al studied leptin and ghrelin concentrations (produced respectively in the adipose tissue and mainly in the stomach) in PD patients with weight loss 8 . The findings in this interesting study, in which plasma leptin levels were reduced and IGF-1 levels were elevated, confirm that altered plasma leptin concentrations are common in PD patients.…”

mentioning

confidence: 99%

Parkinson's disease and body mass index: too much or too little?

Teive

2012

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Parkinson's disease (PD) is the second most common degenerative disease, being characterized by the presence of motor and non-motor symptoms. The former include bradykinesia, rigidity, tremor and postural instability; the latter include depression, sleep disorders, hyposmia, constipation, cognitive dysfunction, dementia and body mass index (BMI) abnormalities 1 . The relationship between BMI and PD is very controversial. In 2010, Hawkes et al. defined a timeline for PD based on the Braak pathological staging ( from stage 1 to 6) and suggested that different brain stem structures are involved in the prodromal phase (estimated to be 20 years) 2. In stage 2, in which there is involvement of the coeruleus/subcoeruleus complex (CSC), the magnocellular portions of the reticular formation and the dorsal raphe nuclei, authors suggested that sleep disorder (REM sleep behavior disorder), depression and obesity are present However, some studies suggest that patients with advanced PD present with malnutrition and lower BMI in relation to controls for several reasons, including the presence of dysphagia, dyskinesia, depression and cognitive problems [3][4][5] . Cassani et al. studied serum adiponectin levels in advanced-stage PD patients with body weight loss and found significantly higher levels of this protein in PD patients than in controls . This pooled data from seven studies and demonstrated that PD patients had a significantly lower BMI than controls, and that patients at Hoehn-Yahr stage 3 had lower BMI in comparison to patients at stage 2 7 . Fiszer et al. studied leptin and ghrelin concentrations (produced respectively in the adipose tissue and mainly in the stomach) in PD patients with weight loss 8 . The findings in this interesting study, in which plasma leptin levels were reduced and IGF-1 levels were elevated, confirm that altered plasma leptin concentrations are common in PD patients. Altered plasma concentrations of orexigenic and anorexigenic peptides (ghrelin and leptin, respectively) lead to alterations in the hypothalamic-pituitary axis 8 . However, PD patients who undergo neurosurgery for a deep brain stimulation (DBS) implant in the subthalamic nucleus can exhibit significant weight gain, underscoring the complex interaction between the hypothalamic-pituitary axis and the basal ganglia 3,5,7,9 . Markali et al. studied the role of ghrelin, neuropeptide Y and leptin in PD patients who had weight gain after DBS implant surgery 9 . They concluded that the introduction of a DBS implant in the subthalamic nucleus temporarily deregulated the hypothalamic secretion of neuropeptide Y and ghrelin, and that weight gain was therefore the result of increased production of ghrelin and leptin 9 .In the current issue of Arquivos de Neuro-Psiquiatria, Morales-Briceño et al. published a very interesting study about overweight PD patients 10 . The authors carried out a cross-sectional study with 177 healthy controls and 177 PD patients. Analyzing BMI, they found that overweight

show abstract

Leptin and ghrelin concentrations and weight loss in Parkinson’s disease

Abstract: These findings confirm that changes of plasma leptin concentration occur in PD patients with loss of weight.

Cited by 76 publications

References 27 publications

Non-motor Symptoms in Parkinson’s Disease

Non-motor Symptoms in Parkinson’s Disease

Clinicotherapeutic Potential of Leptin in Alzheimer’s Disease and Parkinson’s Disease

Parkinson's disease and body mass index: too much or too little?

Contact Info

Product

Resources

About